API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
Details:
The financing will be used for a clinical phase III trial for a fixed-dose combination of artemether-lumefantrine-amodiaquine drug (three existing antimalarial drugs already developed, marketed and sold) against malaria.
Lead Product(s): Artemether,Lumefantrine,Amodiaquine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GHIT Fund
Deal Size: $3.3 million Upfront Cash: Undisclosed
Deal Type: Financing December 13, 2023